Medication

Effect of Sitagliptin on Serum Total Ghrelin Levels in Type 2's

In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels....

FDA Approves Eli Lilly Diabetes Combo Drug Jentadueto

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets....

Metformin May Help Protect Women against Pancreatic Cancer

A new study links the diabetes drug metformin to fewer cases of pancreatic cancer -- at least in women -- but finds other diabetes medications are associated with a higher risk of the disease....

Efficacy and Safety of Bydureon Versus Metformin, Pioglitazone, and Sitagliptin as Monotherapy

In a once weekly injection of exenatide for Drug-Naive Patients with Type 2 Diabetes (DURATION-4) in a 26-week double-blind study they found that exenatide once weekly (EQW) was noninferior to metformin (MET) but not pioglitazone (PIO) and...

Obesity Drug to Get Broader Label

Vivus Inc said the FDA has asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population....

New Predictors May Determine Metabolic Risk in Kids on Atypicals

Two new studies from a team of investigators suggest two possible predictors for the development of metabolic syndrome in children prescribed second-generation antipsychotics (SGAs)....

A Cost Comparison of a Basal-Bolus Regimen Vs. Premixed Insulin in Type 2's

The study investigated the comparative costs of two different insulin regimens in type 2 diabetes based on data from the GINGER study, which investigated the efficacy and safety of an intensified insulin regimen....

FDA Approves BYDUREON™ -- The First Once-Weekly Treatment for Type 2 Diabetes

Once weekly Bydureon will be available in February at the approximate coast of $323 dollars a month which will include 4 injection syringes using 1 per week....

Intranasal Insulin Boosts Cognitive Function

Pooled data suggest that intranasal insulin may have a positive effect on cognition in both impaired and normal subjects....

Successful weight loss with GLP-1 agonists

Summary Insights GLP-1 agonists are effective in weight loss as they delay gastric emptying, induce satiety, and decrease food These agents have been successfully studied in obese,...

Drug Helps Both Patients with and without Diabetes Lose Weight

Researchers found that one class of diabetes drugs can help both diabetes patients and non-diabetes patients alike lose weight....

GLP-1 Help to Control Diabetes after Gastric Bypass

Insulin, glucagon-like peptide-1 positively linked in diabetes patients following gastric bypass surgery....

SPECIAL FEATURE: Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

The regulation of food intake is a complex process involving psychologic, social, and physiologic components. Physiologically, it is generally assumed that food intake is regulated by a central feeding drive that is later counterregulated by...

Weight-Loss Drugs Important in Type 2 Diabetes Management

Optimizing weight "should be a priority" in the management of patients with type 2 diabetes....

EASD: Liraglutide Plus Insulin Does Not Add Weight

The addition of insulin to the treatment regimen of type 2 diabetes patients on liraglutide (Victoza) doesn't wipe out previously seen weight loss, and insulin also appears to help these patients achieve glycemic control, researchers...

Diabetes Mellitus 101 for Medical Professionals, PART 5

In this week's Homerun Slides, we cover such topics as the Potential Mechanisms of...

Once-Weekly Exenatide Similar to Daily Metformin in Monotherapy for Type 2 Diabetes

A direct comparison of four agents as monotherapy in drug-naive patients with type 2 diabetes shows that exenatide once-weekly, metformin, and pioglitazone provide good improvement in glycemic control, while sitagliptin is less...

Pharmacies Can Help Keep Diabetes Patients on Track

Having pharmacies blow the whistle when patients' diabetes medication adherence sagged was helpful in keeping them on the right track....

Diabetes Mellitus 101 for Medical Professionals, PART 4

In this week's Homerun Slides, we continue with Part 4 of our series from Dr. Stanley...

Insulin Therapy May Help Reduce Cardiovascular Disease

Diabetes patients are more susceptible to the development of atherosclerosis than non-diabetics and insulin therapy might help repair atherosclerotic lesions in diabetic patients....

Statins Can Increase Risk of Diabetes

Statin use in postmenopausal women is associated with a significantly increased risk of diabetes mellitus.

Daily Aspirin Tied to Macular Degeneration

Daily aspirin use may protect the heart but hurt the eyes, boosting the risk of AMD....

Diabetes Mellitus 101 for Medical Professionals, PART 3

In this week's set of Homerun Slides, we discuss whether it is possible to delay the...

Should Metformin Be Used for Type 1 Diabetes?

The addition of off-label metformin to insulin therapy to improve insulin sensitivity, promote weight control, and reduce insulin dose requirements in patients with type 1 diabetes, has been assessed in systematic reviews....

For T2DM, the Quality of Guidelines on Oral Meds Varies Dramatically

According to the results of a systematic review, not all practice guidelines on oral medications for type 2 diabetes are consistent with available evidence, and guideline quality varies widely....

New Protein May Be a Treatment Target for Type 1 Diabetes

Researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine and colleagues have discovered a new protein that may play a critical role in how the human body regulates blood sugar levels and could be a new target...

CDC: Hep B Vaccine Needed for Diabetic Adults

Diabetic adults should be vaccinated against hepatitis B virus (HBV) as soon as possible after the diabetes diagnosis is made....

Medication Combo Improved Weight Loss When Added to Lifestyle Modifications

Controlled-release phentermine/topiramate combined with lifestyle modifications appears to be an effective option for sustained treatment of obesity complicated by cardiometabolic disease....

Link between Bio-clock, Glucose Metabolism Found

Researchers at Salk Institute for Biological Studies in the US found proteins that control the body's biological rhythms, known as cryptochromes also interact with metabolic switches that are targeted by certain anti-inflammatory...

SPECIAL FEATURE: The Safety and Extrapancreatic effects of GLP-1 on cardiovascular tissue, adipose tissue, liver, and kidney

GLP-1 receptors are widely expressed in CV, adipose, hepatic, and renal tissue [80,...

Letter from the Editor #606

Happy New Year from all of us at Diabetes in Control. We have provided a lot of information about the most current therapies for diabetes and co-morbidities in recent months and in an effort to bring you more than any other online...

Antibodies Hold Keys to Diabetes Breakthrough

A new diabetes study in the US is developing a diabetes treatment that could help tackle the disease, and not just the symptoms....

Using Statins for Patients with Diabetes without CVD

For primary prevention in patients with diabetes without established cardiovascular disease, statin therapy could reduce the cardiovascular and cerebrovascular events, but not all-cause mortality....

Research Finds That Patients with Diabetes Should Take More Vitamin B12 Daily

People who have type 2 diabetes and are taking metformin should take more than the recommended daily allowance of vitamin B12....

Diabetes Reversed with Investigational Weight Loss Drug

Slightly more than a year of treatment with an investigational obesity drug that the FDA rejected for approval last year reversed type 2 diabetes in 15% of subjects....

Letter from the Editor #605

Next week our patients will all be making their New Year's resolutions and weight loss will be one that many of them make. After a month of eating everything the holidays have to offer they will all be looking for the holy grail of weight...

Antihypertensive Drugs More Effective When Taken at Night

Taking antihypertensive medications at bedtime rather than in the morning has been shown to be associated with an increase in bedtime BP decline toward a dipping pattern and better BP control and reduction in urinary protein...

No Increase in Cancer Risk with Lantus

Sanofi presented fresh data which it says reinforces the safety profile of Lantus, hours after dismissing claims in a study that using the diabetes treatment more than doubled the risk of developing cancer....

Insulin Combination Treats Low Blood Sugar in Diabetes Patients

A combination of two insulins reduced abnormally low blood sugar in diabetes patients....

Breast Cancer Risk Increased in Early Diabetes

There is further damning evidence of an association between diabetes and risk for breast cancer....

Niacin 'AIM's-HIGH but Falls Flat

Niacin boosts HDL cholesterol without benefit for clinical outcomes in otherwise well-treated patients, according to a results of a halted, and perhaps inconclusive, clinical trial....

Antipsychotics Linked to Childhood Diabetes

Diabetes may be substantially more likely for children taking second-generation atypical antipsychotics....

GLP-1's Function in Preserving B-cells

Associations between acute glucose lowering and improved acute insulin secretory responses suggest improved β-cell function. Comparing and assessing effects of pharmacological therapies used to control hyperglycemia on β-cell...

Letter from the Editor #600: Top 10 Physical Activity Myths Demystified and Reversing Beta Cell Failure

According to Webster's, a "publisher is responsible for the selection, preparation, and distribution of information," and usually has no involvement in the actual development of content or material. However, when the publisher has over...

New Possible DPP-4/TZD Combo for Jan 2012

Takeda announced that the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy...

Resveratrol Improves Metabolism in Obese Men

Resveratrol, an ingredient found in red wine, may improve the health of obese men....

FDA Recommends Vytorin for CVD Prevention in Predialysis CKD Patients

An FDA advisory committee has recommended unanimously that the ezetimibe-simvastatin combination pill (Vytorin) be approved for prevention of cardiovascular disease in CKD patients who are not on dialysis....

New Study Supports Cardiovascular Safety of Bristol-Myers Squibb/AstraZeneca's SGLT2 Drug Dapagliflozin in Type 2's

Dapagliflozin, an inhibitor of SGLT2 as an adjunct to diet and exercise, is being investigated to evaluate its safety and its efficacy on blood sugar levels in adults with type 2 diabetes....

Regular U-500 Insulin May Have Longer Duration of Action

Although the pharmacokinetics and pharmacodynamics of high-dose human regular U-500 and human regular U-100 insulin are similar, the U-500 formulation may have a longer duration of action....

Editor's Note: The Best of the Best of Our GLP-1 Series

When it comes to knowledge sometimes you just can't get enough when you are interested in a topic. Over the past six months we have spent a lot of time giving you the most-up-to-date and relevant information on GLP-1 therapy that we could find. We...

Editor's Note: Pre-School Children with Diabetes

Have you ever had a patient who is a pre-school child with diabetes? Usually this means that the parents are trying to stay in control and the child wants more independence.

Incretins, Part 7 of 7

This week, we wrap up our seven part series of Homerun Slides on Incretins with a...

Tight Glycemic Control Won't Cut Diabetes Patients' Heart Failure Risk

Intensive blood glucose control won't reduce the risk of heart failure in patients with type 2 diabetes -- and tight control using a thiazolidinedione may actually increase the risk....

Lilly and Amylin Agree to End Diabetes Alliance

They announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies....

New Drug Cuts Blood Supply to Fat Cells for Weight Loss without Exercise

Adipotide basically reduces the blood supply specifically to fat cells, causing them to simply wither away....

FDA Warns Fenofibric Acid May Not Cut Cardiac Risk

The FDA has ordered that the label for fenofibric acid (Trilipix) be changed to indicate that the lipid-lowering drug has not been shown to reduce the risk of heart attack or stroke....

Exercise Impact Lessened Slightly by Metformin in Prediabetes

For men and women with prediabetes, insulin sensitivity increases to a similar extent with exercise training, metformin, or a combination of the two, with metformin impacting slightly on the effect of exercise....

Diabetes Drug Also Reduces Inflammation

A GLP-1 drug prescribed to help patients with type 2 diabetes improve blood-sugar control also has a powerful anti-inflammatory effect, and the effect was observed within 2 hours following a single dose....

Pyridoxamine May Slow Early Diabetic Nephropathy

Pyridoxamine (vitamin B6) is known to be an effective scavenger of reactive oxygen species and a potent inhibitor of advanced glycation end products. A new study demonstrated the benefits for patients with Type 2...

Newborn Period Crucial Time Window to Prevent Later Diabetes

A new approach to prevent type 2 diabetes may be on the horizon. The use of exendin-4 in newborns may prevent diabetes later in life....

FDA Panel Says Vytorin Okay for Some Kidney Disease Patients

An FDA advisory committee has recommended unanimously that the ezetimibe-simvastatin combination pill (Vytorin) be approved for prevention of cardiovascular disease in CKD patients who are not on dialysis....

Diabetes Patients Have Double the Risk for Hepatitis B Infection

The CDC held a hearing on a recommendation that patients with diabetes receive immunization with the hepatitis B vaccine....

Not Looking Good for FDA Approval of the New First in Class SGLT2 Drugs

FDA delays verdict on Astra/Bristol SGLT2 diabetes pill until Jan 28th, the same day they are deciding on the possible approval of Bydureon....

Intensification of Diabetes Treatment: Basal vs. Postprandial Treatment

Basal hyperglycemia intervention accounts for one-third of total hyperglycemia after basal insulin treatment and two-thirds after alternative methods....

The Low-Down on Incretin Therapy

Incretins were a hot topic at this year's EASD....

Role of DPP-4 Inhibitors in Clinical Practice

The dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2...

Use of Incretin-Related Medications Will Grow by 47 Percent

A new study found that the incretin-related medications will see the strongest growth among type 2 diabetes drugs over the next nine years....

Insulin Sensitizers Limit Muscle Loss in Older Diabetes Patients

Insulin sensitizers may limit the muscle loss seen in elderly men with type 2 diabetes....

FDA Approves BYETTA® for Use with Insulin Glargine in the U.S.

Patients in pivotal study achieved better glycemic control and lost on average 4 pounds without increased risk for hypoglycemia versus insulin glargine alone, dropping their A1c 1.7%....

Metformin in Gestational Diabetes

Children exposed to metformin had larger measures of subcutaneous fat, but overall body fat was the same as in children whose mothers were treated with insulin alone....

Diabetes Medication Compliance a Major U.S. Issue

We need to do a better job. Research by the New England Healthcare Institute shows that patients who don't take their medications as prescribed, cost the U.S. health care system an estimated $290 billion in avoidable medical spending each...

Sitagliptin for Type 1 Diabetes

Sitagliptin significantly improved overall glucose control, including postprandial and 24-h glucose control, in adult patients with Type 1 diabetes, while significantly reducing prandial insulin requirements....

Exenatide vs. Sitagliptin on 24H Glucose

Compared to sitagliptin, exenatide showed significantly lower average 24-h glucose, 2-h postprandial glucose (PPG), glucagon, caloric intake and improved homeostasis model assessment of beta-cell function (HOMA-B)....

Diabetes Drug May Have Plaque Benefit

Pioglitazone (Actos) may reduce atherosclerotic plaque inflammation, independent of its glucose-lowering effects....

FDA Approves Diabetes and Cholesterol-Lowering Drug Combo: Juvisync®

Known as Juvisync (Merck), the new medication combines sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used for glycemia control, with the cholesterol-lowering simvastatin....

Obesity Drug Contrave Back on Track

The investigational weight-loss combination of naltrexone standard release and bupropion standard release (Contrave) reduces the predicted 10-year risk of cardiovascular events, an analysis of four phase III trials...

No Increased CVD Events with DPP-4 Inhibitors

Offering a rare glimmer of good cardiovascular-disease news for a diabetes drug, a new meta-analysis suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors, at worst, do not increase the risk of cardiovascular events and, at best, may...

Simvastatin Beats Metformin in PCOS Therapy

Both simvastatin and metformin can prompt improvements in women with polycystic ovary syndrome (PCOS) but simvastatin seems to have a stronger effect, new research suggests....

EASD: Intensified Treatment with Basal Insulin Improves Control and Weight Loss

Adding insulin detemir to a treatment regimen of metformin and liraglutide improved glycemic control and led to sustained weight loss for up to 52 weeks in patients with type 2 diabetes....

EASD: 'Gliptin's' May Be Heart Savers

While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes patients, researchers made a surprising discovery –- treatment with the so-called gliptin class...

New First in Class Glucagon Antagonists Show Promise for Diabetes

New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes....

EASD: Positive Results for Two SGLT2 Inhibitors

The investigational drug ipragliflozin improved glycemic control and decreased body weight and blood pressure, according to the phase III BRIGHTEN study....

Miglitol Increases GLP-1 Levels for Patients Treated with Sitagliptin

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin....

Communicating Uncertainties About Prescription Drugs to the Public

 A National Randomized Trial Lisa M. Schwartz, MD, MS; Steven Woloshin, MD, MS Background Many new drugs are aggressively promoted. The public may ...

EASD: First Injection-free Once-A-Year GLP-1

ITCA 650, injection-free continuous delivery of GLP-1 therapy, demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI AEs typically associated with this...

EASD: Twice-Daily Aspirin Betters Platelet Inhibition for People with Diabetes

Twice-daily aspirin administration, but not a once-daily doubling of the dose, appears to provide good inhibition of platelet cyclooxygenase (COX)-1 in diabetic patients who have rapid recovery of COX-1 activity, and might enhance...

Can Incretins Work in Type 1 Diabetes?

Adding the type 2 diabetes drug liraglutide (Victoza) to insulin therapy improves glycemic control in patients with type 1 disease, researchers said....

Newly Diagnosed Type 2 Initiated on Basal Insulin with Oral Antidiabetic Med

In newly diagnosed type 2 diabetes, therapy with oral antidiabetes drugs plus basal insulin (OAD+insulin) has had favorable outcomes on recovery and maintenance of β-cell function and protracted glycemic remission compared to...

Treatment with Inspra Shows Reduction in CV Mortality for those at High Risk

Even patients with such high-risk features as diabetes or renal compromise showed highly significant drops in CV mortality or heart-failure hospitalizations from treatment with eplerenone (Inspra, Pfizer) in EMPHASIS-HF....

Possible Hope for Type 1's

Patients with type 1 diabetes have been offered new hope as scientists test a drug that could save them from a lifetime of injections....

Novel HDL-Raising Drug Appears Safe

A novel cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, raised HDL cholesterol without any safety concerns in phase IIb dal-VESSEL trial, but it remains to be seen whether that boost in HDL will improve clinical...

Lilly Updates Humulin R U-500 label to Prevent Errors

The labeling of HUMULIN R (insulin regular) U-500 was updated recently. The new label includes information about medication errors and their prevention....

New Drug Improves Lipids and Glucose in Metabolic Impairment

In two recent trials, the investigational drug GFT505 improved lipid and glucose disorders in abdominally obese patients with combined dyslipidemias or prediabetes....

Add-on Dapagliflozin Improves Diabetes Control without Weight Gain

The investigational glucose-lowering drug dapagliflozin improved glycemic control in patients with type 2 diabetes already on metformin, and it promoted significant weight loss, in a phase II trial....

Pioglitazone Gets New Cancer Risk Labeling

The FDA has approved updated label information for pioglitazone (Actos) and medications that contain it, following its warning in June about bladder cancer risk with the drug....

Lilly Resubmits Bydureon to FDA

Bydureon could be available by Feb or March of 2012 or even sooner. Because Bydureon is the same drug as Byetta (which has been in the market for over 5 years and basically is the same drug) except that Bydureon only needs to be injected...

Takeda Resubmits New Drug Applications in the U.S. for their Alogliptin and Alogliptin/Pioglitazone Combo

Takeda announced today that it resubmitted two NDA's to the FDA for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet....

Weight-Based Insulin Dosing Safe at Recommended Doses

Weight-based insulin doses up to 0.6 units per kilogram are associated with a low risk of hypoglycemia, according to a new report....

Why the FDA Said No to First In Class Dapagliflozin

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9 to 6 against recommending the approval of the first in class novel antidiabetic agent dapagliflozin, largely because of fears that the product may cause breast...

Diabetes Drug Dapagliflozin Rejected by FDA Panel

A federal advisory committee voted 9 to 6 on July 19 that a first-of-its-kind diabetes drug should not be approved for use because of safety concerns, including a possible increased risk of breast and bladder cancers....

'Good' Cholesterol Raised by Experimental Drug, May Impact Diabetes Control

  A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs....

New Target Shows Promise for Type 2 Diabetes

An investigational first in class compound with a novel mechanism of action appears to improve glycemic control in type 2 diabetes....

Early Metformin Therapy Delayed Onset, and Prevention of PCOS

Recent data suggest that treatment with metformin during late childhood or early puberty may impede or prevent the development of polycystic ovary syndrome in girls at high risk for the disease....

Lilly Prepares to Launch Bydureon in US

Eli Lilly aims to bring its once-a-week diabetes injection Bydureon to US markets in the first half of next year....

Insulin Aspart by Jet Injection Enhances Absorption

Using jet injection of insulin instead of conventional pen devices can halve the time required to reach appropriate glucose-lowering effects....

Exenatide Reduced Heart Failure Risk by 50 Percent in Type 2's

Data from a retrospective analysis have demonstrated a reduction in the probability for patients with type 2 diabetes to develop heart failure when adding exenatide injection to current treatment. The reduction was particularly noted in...

Sitagliptin Shows Anti-inflammatory Activity in Diabetes Patients

  The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin exerts an anti-inflammatory effect in patients with type 2 diabetes at the cellular and molecular level....

New Target Shows Promise for Type 2 Diabetes

An investigational compound with a novel mechanism of action appears to improve glycemic control in type 2 diabetes....

Liraglutide with Insulin Effective in Type 1's

Treatment with Liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function....

Exenatide tQT Study Showed No Prolongation of QT Interval

Results will be included in the BYDUREON™ New Drug Application Resubmission in the Third Quarter of 2011....

High Aspirin Dosage May Curb Heart Attack Risk in Diabetes

New research from scientists in Canada has revealed that taking aspirin every day could offer benefits for those managing their diabetes....

Is Inhaled Insulin Closer to Reality?

New data on the inhalable insulin product Technosphere Insulin Afrezza, from MannKind Corp., indicate that the treatment confers no discernible risk for increased cardiovascular (CV) events, while another study examined patient...

Liraglutide Shows Potential as Treatment for Weight Loss in Non-Diabetics

Liraglutide, recently approved in the US for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients....

Chantix Linked to Heart Risks

Users of the smoking-cessation drug varenicline (Chantix) had a small but statistically significant increase in the risk of cardiovascular events, a meta-analysis of randomized trials showed....

BYDUREON™ Receives Marketing Authorization in Europe

BYDUREON™ Receives Marketing Authorization in Europe BYDUREON showed statistically significant improvements in glycemic control based on reduction of A1C (a measure of average blood sugar over three months) between 1.5...

Experimental TZD Balaglitazone Shows Fewer Side Effects

  Balaglitazone, an experimental thiazolidinedione derivative, was slightly less effective than pioglitazone but had fewer side effects in patients with type 2 diabetes in a recent phase III trial....

Osteoarthritis Drug Diacerein Improves Glycemic Control in Type 2 Diabetes

In a study, two months of treatment with the anti-inflammatory agent diacerein improved insulin secretion and dropped A1C levels in type 2 diabetes patients from 8.3% to 7.0%, within 60 days....

Diuretic-ARB Combo Best to Lower BP

For patients with stage 2 systolic hypertension, an investigational, fixed-dose combination of an angiotensin II receptor blocker (ARB) with a diuretic, reduced blood pressure more than the approved ARB-diuretic pairing, a randomized trial...

New Polypill Data Predicts a Halving of CV Events

The first randomized, placebo-controlled study of a polypill has suggested that use of such a product in primary prevention could bring about a halving of heart disease and stroke events....

Preventing Medication Errors

Institute for Safe Medication Practices